Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Today's Trading !!!!

<< Previous

Bullboard Posts

Next >>

Comment by PTBaileyon Oct 13, 2021 5:28pm

209 Views

Post# 34003003

RE:Today's Trading !!!!

Red~One wrote: Wow B warrants up for sale, must be those damn naked shorts covering again or maybe Salzman "making more room" for payments

This is couple of times now you refer to Salzman making room for payments which is referencing a post I made on another board. So you say you are here to correct the pumpers and bashers. If so make the informed correction instead of the BS comments. Not helpful.

<< Previous

Bullboard Posts

Next >>

A potential breakthrough in spinal cord and optic nerve injury treatment